Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 958-963

  Pavelka, Karel ^a,b   Forejtová, Šárka ^a,b   Štolfa, Jiří ^a,b   Chroust, Karel ^c   Burešová, Lucie ^c   Mann, Heřman ^a,b   Vencovský, Jiří ^a,b  

^a INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Ankylosing spondylitis; Anti TNF therapy

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMPLOYMENT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENDER; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; RISK FACTOR; SURVIVAL; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; CZECH REPUBLIC; DRUG COSTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PATIENT COMPLIANCE; REGISTRIES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76649091242     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLAB27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67.
2. FOREJTOVA S, MANN H, STOLFA J et al.: Factors influencing health status and disability of patiens with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 2008; 27: 1005-13.
3. ZOCHLING J, VAN DER HEIJDE D, BURGOSVARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
4. MANN H, PAVELKA K: Doporučení ASAS a EULAR pro péči o nemocné s ankylozující spondilitidou. Lékařské Listy 2006; 14-6.
5. DAGFINRUD H, KVIEN TK, HAGEN KB: Physiotherapy interventiones for ankylosing spondylitis. Cochrane Database Syst Rev 2004; 4: CD002822.
6. WANDERS A, VAN DER HEIJDE D, LANDEWE R et al.: Nonsteroidal antiiflammatory drugs reduce radiographic progression in patiens with ankylosing spondylitis. Arthritis Rheum 2005; 52: 1756-65.
7. LUUKKAINEN R, NISSILA M, ASIKAINEN E et al.: Periarticular corticosteroid treatment of the sacroiliac joint in patiens with seronegative spondylarthropathy. Clin Exp Rheumatol 1999; 17: 88-90.
8. CHEN J, LIU C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005; 2: CD004800.
9. BRAUN J, BARALIAKOS X, BRANDT J et al.: Persistent clinical response to the anti-TNF-alpha antibody infliximab in patiens with ankylosing spondylitis over 3 years. Rheumatology 2005; 44: 670-6.
10. VAN DER HEIJDE D, KIVITZ A, SCHIFF MH et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54: 2136-46.
11. DAVIS JC JR, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
12. BRAUN J, BARALIAKOS X, LISTING J, SIEPER J: Decraesed incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51.
13. PAVELKA K, STOLFA J, VENCOVSKY J: Doplněk standardních léčebných postupů u ankylozující spondylitidy. Čes Revmatol 2004; 12: 30-35.
14. GARRET S, JENKINSON T, KENNEDY LE, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease activity index. J Rheumatol 1994; 21: 2286-91.
15. KONTTINEN L, TUOMPO R, UNSITALO T et al.: Anti TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol 2007; 26: 1693-700.
16. COATES LC, COWKWELL LS, NG NF et al.: Real life experience confirms sustained response to long term biologics and switching in ankylosing spondylitis. Rheumatology 2008; 47: 897-900.
17. RUDWALEIT M, LISTING J, BRANDT J. BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-70.
18. PAVELKA K, JAROSOVA K, CHROUST K et al.: Efficacy of switching between TNF inhibitors for the treatment of RA in the Czech National Register of biologicals ATTRA. Ann Rheum Dis 2008; (Suppl. II) 67: 327.
19. ZOCHLING J, BRAUN J: Quality indicators, guidelines and outcome measures in ankylosing spondylitis. Clin Exp Rheumatol 2007; 25 (Suppl. 47): 147-52.
20. HAIBEL H SONG IH RUDWALEIT M et al.: Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol 2008; 26: 247-52.